No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy

Cancer Biology and Therapy

Volumn 10, Issue 9, 2010, Pages 854-859

  Yuan, Peng ^a   Liu, Li ^b   Wu, Chen ^a   Zhong, Rong ^b   Yu, Dianke ^a   Wu, Jing ^b   Xu, Yihua ^b   Nie, Shaofa ^b   Miao, Xiaoping ^b   Sun, Yan ^a   Xu, Binghe ^a   Lin, Dongxin ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Haplotype; Non small cell lung cancer; Overall survival; Platinum drug; Polymorphism; Progression free survival; XRCC1

Indexed keywords

CARBOPLATIN; CISPLATIN; OXALIPLATIN; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 78549243373     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.9.13238     Document Type: Article

References (37)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc 2008; 83:584-94. (Pubitemid 351720831)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55:74-108.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005; 55:74-108.
4. Cobo Dols M, Gil Calle S, Villar Chamorro E, Ales Diaz I, Montesa Pino A, Alcaide Garcia J, et al. New prospects in non-small cell lung cancer treatment: Pharmacogenomics. Oncologia 2006; 29:55-64.
5. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002; 94:1091-9. (Pubitemid 34830729)
6. Price N. Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. Clin Lung Cancer 2004; 6:79-82.
7. Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009; 10:1001-10.
8. JG D. pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit 2004.
9. West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol 2009; 4:1029-39.
10. Rosell R, Taron M, Alberola V, Massuti B, Felip E. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003; 41:97-102.
11. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998; 18:3563-71.
12. Schneider J, Classen V, Helmig S. XRCC1 polymorphism and lung cancer risk. Expert Rev Mol Diagn 2008; 8:761-80.
13. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006; 27:560-7. (Pubitemid 43372885)
14. Shen M, Berndt SI, Rothman N, Mumford JL, He X, Yeager M, et al. Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China. Anticancer Res 2005; 25:537-42.
15. Xing D, Qi J, Miao X, Lu W, Tan W, Lin D. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer 2002; 100:600-5.
16. Hong CY, Xu Q, Yue Z, Zhang Y, Yuan Y. Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism. Chin J Cancer 2009; 28:1291-7.
17. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009; 65:230-6.
18. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22:2594-601.
19. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10:118-23.
20. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, et al. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 2007; 13:2876-81.
21. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, et al. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 2009; 10:859-64.
22. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acid Res 1976; 3:2303-8.
23. Cao Y, Miao XP, Huang MY, Deng L, Hu LF, Ernberg I, et al. Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer 2006; 6:167.
24. Xing D, Tan W, Wei Q, Lin D. Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer 2002; 38:123-9. (Pubitemid 35157754)
25. Garcia-Campelo R, Alonso-Curbera G, Anton Aparicio LM, Rosell R. Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother 2005; 6:2015-26.
26. Belani CP, Langer C. First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 2002; 38:13-9.
27. Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene 2006; 25:1612-9.
28. Tebbs RS, Flannery ML, Meneses JJ, Hartmann A, Tucker JD, Thompson LH, et al. Requirement for the XRCC1 DNA base excision repair gene during early mouse development. Dev Biol 1999; 208:513-29.
29. Lamerdin JE, Montgomery MA, Stilwagen SA, Scheidecker LK, Tebbs RS, Brookman KW, et al. Xeroderma pigmentosum and trichot Genomic sequence comparison of the human and mouse XRCC1 DNA repair gene regions. Genomics 1995; 25:547-54.
30. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 2005; 162:925-42. (Pubitemid 41619464)
31. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998; 58:604-8.
32. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 2007; 4:59-71.
33. Kiyohara C, Takayama K, Nakanishi Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 2006; 54:267-83. (Pubitemid 44634141)
34. Sreeja L, Syamala VS, Syamala V, Hariharan S, Raveendran PB, Vijayalekshmi RV, et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol 2008; 134:645-52.
35. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17:668-75.
36. Yoon SM, Hong YC, Park HJ, Lee JE, Kim SY, Kim JH, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63:885-91.
37. Wu X, Hildebrandt MA, Chang DW. Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications. Cancer Metastasis Rev 2009; 28:269-80.